Labcorp Holdings
LH
311.97
+0.26
+0.08%
Labcorp Holdings
US · LH
#790 by market cap
Listed 1970
311.97
+0.26
+0.08%
Live - 5344 symbols - heartbeat 556s ago
· 2026-10-08 08:49
Pre-market
312.49
+0.17%
After-hours
311.97
0.00%
- Market cap
- 25.30B
- P/E (TTM)i
- 25.80
- P/Bi
- 2.94
- EPSi
- 10.46
- Div yieldi
- 0.92%
- 52W posi
- 71%
Reader sentiment
Are you bullish or bearish on LH?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 3.32, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +7.25% YoY
Margins
- Gross margin
- 28.76%
- Operating margin
- 10.87%
- Net margin
- 6.28%
Key ratios & quality
- Enterprise valuei
- 30.55B
- Altman Z-Scorei
- 3.32
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 11.33B | 11.55B | 13.98B | 13.14B | 11.86B | 12.16B | 13.01B | 13.95B |
| Gross profit | 3.18B | 3.25B | 4.95B | 4.99B | 3.71B | 3.36B | 3.62B | 4.01B |
| Selling & admin expenses | 1.57B | 1.62B | 1.73B | 1.69B | 1.76B | 2.02B | 2.23B | 2.22B |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 1.37B | 1.38B | 2.95B | 3.07B | 1.75B | 1.12B | 1.14B | 1.52B |
| Pretax profit | 1.27B | 1.10B | 2.22B | 2.89B | 1.24B | 568.90M | 959.50M | 1.11B |
| Tax | 384.40M | 280.00M | 662.10M | 690.00M | 233.90M | 188.50M | 212.40M | 229.80M |
| Net profit | 883.90M | 824.90M | 1.56B | 2.38B | 1.28B | 419.20M | 747.10M | 877.70M |
| Basic EPS | 9 | 8 | 16 | 25 | 14 | 5 | 9 | 11 |
| Diluted EPS | 8.61 | 8.35 | 15.88 | 24.39 | 13.97 | 4.77 | 8.84 | 10.46 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 3.35B | 3.53B | 3.56B | 3.52B | 3.54B | 3.73B |
| Gross profit | 948.00M | 1.05B | 1.03B | 993.20M | 1.01B | 1.11B |
| Selling & admin expenses | 546.00M | 579.30M | 552.40M | 538.60M | 551.00M | 577.20M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 332.40M | 398.60M | 403.20M | 382.00M | 387.20M | 456.70M |
| Pretax profit | 275.20M | 304.70M | 337.00M | 190.60M | 319.70M | 386.40M |
| Tax | 62.20M | 66.40M | 75.50M | 25.70M | 41.70M | 87.30M |
| Net profit | 213.00M | 238.30M | 261.50M | 164.90M | 278.00M | 299.10M |
| Basic EPS | 3 | 3 | 3 | 2 | 3 | 4 |
| Diluted EPS | 2.52 | 2.84 | 3.12 | 1.98 | 3.35 | 3.64 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 2.84B | 2.98B | 5.13B | 5.33B | 4.63B | 3.77B | 4.81B | 4.02B |
| Cash & ST investments | 426.80M | 337.50M | 1.32B | 1.47B | 320.60M | 536.80M | 1.52B | 532.30M |
| Inventory | 237.30M | 244.70M | 423.20M | 401.40M | 470.60M | 474.60M | 493.20M | 534.70M |
| Total assets | 16.19B | 18.05B | 20.07B | 20.39B | 20.16B | 16.73B | 18.38B | 18.39B |
| Total current liabilities | 1.88B | 2.66B | 3.08B | 2.78B | 3.08B | 3.23B | 3.33B | 2.82B |
| Short-term debt | 17.90M | 630.10M | 575.40M | 199.00M | 471.10M | 1.17B | 1.19B | 695.80M |
| Long-term debt | 5.99B | 5.79B | 5.42B | 5.42B | 5.04B | 4.05B | 5.33B | 5.08B |
| Total liabilities | 9,194,800,000.00 | 10,459,300,000.00 | 10,614,400,000.00 | 10,091,400,000.00 | 10,039,600,000.00 | 8,834,600,000.00 | 10,312,500,000.00 | 9,756,000,000.00 |
| Total equity | 6.99B | 7.59B | 9.46B | 10.29B | 10.12B | 7.89B | 8.07B | 8.64B |
| Retained earnings | 7.08B | 7.90B | 9.48B | 10.46B | 10.58B | 7.89B | 8.30B | 8.64B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 3.79B | 4.09B | 4.08B | 4.02B | 4.56B | 3.81B |
| Cash & ST investments | 369.40M | 647.30M | 598.10M | 532.30M | 981.10M | 141.80M |
| Inventory | 488.30M | 508.10M | 521.50M | 534.70M | 497.70M | 562.20M |
| Total assets | 17.60B | 18.06B | 18.26B | 18.39B | 19.09B | 18.53B |
| Total current liabilities | 2.06B | 2.72B | 2.63B | 2.82B | 2.64B | 2.12B |
| Short-term debt | 188.00M | 690.00M | 691.10M | 695.80M | 688.20M | 185.90M |
| Long-term debt | 5.57B | 5.08B | 5.08B | 5.08B | 5.83B | 5.86B |
| Total liabilities | 9,282,100,000.00 | 9,570,500,000.00 | 9,548,600,000.00 | 9,756,000,000.00 | 10,341,600,000.00 | 9,909,100,000.00 |
| Total equity | 8.32B | 8.49B | 8.71B | 8.64B | 8.75B | 8.62B |
| Retained earnings | 8.46B | 8.50B | 8.70B | 8.64B | 8.78B | 8.70B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 1.31B | 1.44B | 2.14B | 3.11B | 1.96B | 1.33B | 1.59B | 1.64B |
| Depreciation & amortization | 552.10M | 577.20M | 624.70M | 577.00M | 537.20M | 577.30M | 643.50M | 681.10M |
| Free cash flow | 925.60M | 1.04B | 1.75B | 2.69B | 1.53B | 874.10M | 1.10B | 1.21B |
| Dividends paid | -- | -- | 0 | 0 | -195.20M | -254.00M | -243.10M | -240.70M |
| Stock buybacks / issuance | -700.00M | -450.00M | -100.00M | -1.67B | -1.10B | -1.00B | -250.10M | -450.00M |
| Ending cash balance | 426.80M | 337.50M | 1.32B | 1.38B | 320.60M | 536.80M | 1.52B | 532.30M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 18.50M | 620.60M | 387.20M | 614.20M | 191.50M | 445.50M |
| Depreciation & amortization | 166.80M | 170.30M | 171.00M | 173.00M | 173.30M | 179.00M |
| Free cash flow | -107.50M | 542.70M | 280.50M | 490.30M | 70.50M | 313.90M |
| Dividends paid | -61.60M | -59.90M | -59.90M | -59.30M | -61.20M | -58.70M |
| Stock buybacks / issuance | 0 | -200.00M | -25.00M | -225.00M | -98.00M | -353.80M |
| Ending cash balance | 369.40M | 647.30M | 598.10M | 532.30M | 981.10M | 141.80M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 12.81 | 11.33 | 18.39 | 24.22 | 12.56 | 4.65 | 9.37 | 10.51 |
| ROA %i | 5.40 | 4.81 | 8.16 | 11.75 | 6.31 | 2.27 | 4.25 | 4.77 |
| ROIC %i | 7.92 | 7.24 | 11.05 | 15.51 | 8.64 | 3.65 | 6.23 | 6.92 |
| 5-year avg ROE %i | 15.38 | 13.80 | 15.20 | 17.31 | 15.83 | 14.19 | 13.80 | 12.24 |
| EBIT margin %i | 13.35 | 11.65 | 17.36 | 20.71 | 11.85 | 6.32 | 8.98 | 9.54 |
| FCF / sales %i | 8.17 | 9.04 | 12.55 | 16.43 | 9.91 | 7.19 | 8.42 | 8.64 |
| Current ratioi | 1.51 | 1.12 | 1.66 | 1.92 | 1.50 | 1.17 | 1.44 | 1.42 |
| Quick ratioi | 1.22 | 0.89 | 1.41 | 1.60 | 0.75 | 0.82 | 1.09 | 0.99 |
| Debt / assetsi | 37.44 | 39.39 | 33.66 | 31.11 | 30.99 | 35.60 | 39.57 | 35.48 |
| LT debt / equityi | 86.67 | 85.60 | 65.50 | 59.80 | 57.20 | 60.73 | 75.53 | 67.64 |
| Interest coveragei | 6.19 | 5.59 | 11.70 | 15.74 | 9.78 | 3.85 | 5.61 | 5.94 |
| Revenue CAGR (3Y) %i | 9.30 | 6.55 | 10.69 | 5.04 | 0.88 | -4.54 | -0.32 | 5.55 |
| Net income CAGR (3Y) %i | 26.40 | 4.99 | 8.24 | 39.08 | 15.80 | -35.48 | -32.05 | -11.84 |
| FCF CAGR (3Y) %i | 8.40 | 4.39 | 14.03 | 42.67 | 13.49 | -20.71 | -25.85 | -7.56 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 8.99 | 9.27 | 10.14 | 10.51 | 11.05 | 11.74 |
| ROA %i | 4.28 | 4.39 | 4.64 | 4.77 | 5.13 | 5.48 |
| ROIC %i | 6.26 | 6.49 | 6.66 | 6.92 | 7.30 | 7.81 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 8.76 | 8.91 | 9.69 | 9.54 | 9.72 | 10.18 |
| FCF / sales %i | 8.74 | 9.36 | 10.03 | 8.64 | 9.78 | 8.05 |
| Current ratioi | 1.84 | 1.50 | 1.55 | 1.42 | 1.73 | 1.80 |
| Quick ratioi | 1.28 | 1.08 | 1.09 | 0.99 | 1.30 | 1.25 |
| Debt / assetsi | 37.04 | 36.25 | 35.76 | 35.48 | 37.93 | 36.51 |
| LT debt / equityi | 76.22 | 69.12 | 67.14 | 67.64 | 75.07 | 76.45 |
| Interest coveragei | 5.31 | 5.29 | 5.73 | 5.94 | 6.16 | 6.43 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Diagnostics Laboratories (Dx) is the largest reported line at 77.74% of revenue, across 3 reported segments.
- The next-largest line, Biopharma Laboratory Services (BLS), is a distant second at 22.41% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Diagnostics Laboratories (Dx)77.74%
Biopharma Laboratory Services (BLS)22.41%
Quote time 2026-10-08 08:49:44 · For reference only, not investment advice and not tailored to your situation.